Health Canada has approved Calquence (acalabrutinib), an oral Bruton’s tyrosine kinase inhibitor, as monotherapy or in combination with obinutuzumab in the first-line setting, and as monotherapy for relapsed/refractory (r/r) disease for the treatment of adult patients with chronic lymphocytic leukemia.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
